Evidence map›Paper›PMID 37227510›Full record

ArticleAmino acids2023

Screening of AS101 analog, organotellurolate (IV) compound 2 for its in vitro biocompatibility, anticancer, and antibacterial activities.

Abhishek Tripathi, Amreen Khan, Pallavi Kiran, Harsha Shetty, Rohit Srivastava

Abstract read
PubMed Publisher
In one paragraph

Article in Amino acids, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Tellurium and Nano-Tellurium: Medicine or Poison?Nanomaterials (Basel, Switzerland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Abhishek Tripathi *Department of Chemistry, Indian Institute of Technology Bombay, Mumbai, 400076, India.
Amreen Khan *Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai, 400076, India.
Pallavi Kiran *Department of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai, 400076, India.
Harsha ShettyDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai, 400076, India.
Rohit SrivastavaDepartment of Biosciences and Bioengineering, Indian Institute of Technology Bombay, Mumbai, 400076, India. rsrivasta@iitb.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Organotellurium compounds are being well researched as potential candidates for their functional roles in therapeutic and clinical biology. Here, we report the in vitro anticancer and antibacterial activities of an AS101 analog, cyclic zwitterionic organotellurolate (IV) compound 2 [Te

Indexed as

Antineoplastic AgentsBreast NeoplasmsAnti-Bacterial AgentsEthylenesFemaleHumansMicrobial Sensitivity Testsammonium trichloro(dioxoethylene-O,O'-)tellurateAnti-Bacterial AgentsAntineoplastic AgentsEthylenesAntibacterial activityAnticancer activityAS101Organotellurolate (IV) compoundTellurocysteine

Identifiers

PMID37227510

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.